Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

or 12 cents per common share on a GAAP basis and 17 cents per common share when excluding other specified items.

GAAP net sales for the 2007 fourth quarter totaled $3.7 billion as compared to $2.7 billion in the fourth quarter of 2006. Adjusted net sales (GAAP net sales plus an assumed 50 percent of global cholesterol joint venture net sales - see table below on page 19 and hereinafter referred to as "adjusted sales") would have totaled $4.4 billion. Schering-Plough does not record sales of its cholesterol joint venture with Merck & Co., Inc. (Merck), as the venture is accounted for under the equity method.
The 2007 full year was significant for many important achievements:

-- Completing the acquisition of Organon BioSciences N.V. for

approximately 11 billion euro, thus adding new categories - women's

health and anesthesia/psychiatry - and making Schering-Plough one of

the world's leading animal health companies;

-- Growing cholesterol franchise sales to $5.2 billion in 2007, with U.S.

sales up 26 percent and international sales up 70 percent;

-- Growing sales by double digits in each major customer segment -

Prescription Pharmaceuticals, Consumer Health Care and Animal Health;

-- Gaining strength in global markets, with sales in international markets

representing more than 60 percent of total GAAP net sales;

-- Continuing to expand the company's businesses with new products and

indications while extending its presence in fast-growing emerging

markets, such as China, Brazil and Russia;

-- Strengthening the research pipeline with new compounds and by advancing

development to Phase III of such agents as a thrombin receptor

antagonist (TRA) for atherothrombosis and vicriviroc for HIV; both are

among the company's four compounds designated "fast track" by the U.S.

Food and Drug Administration (FDA); and


'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), ... CE Mark approval for its Neurostep(TM) System, the ... used on peripheral nerves. CE Mark represents regulatory ... in any of the Member States of the ...
... NOVATO, Calif., Feb. 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... National Health Surveillance Agency, has granted BioMarin marketing approval ... Mucopolysaccharidosis VI (MPS VI)."We are very pleased to receive ... largest known number of affected MPS VI patients in ...
... 3 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... that Jerry McMahon, Ph.D.,chairman and CEO, will present at ... Tuesday, February 10, at 10 a.m. Eastern Time at ... Dr. McMahon will provide a corporate overview, including a ...
Cached Biology Technology:Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference 2
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Bowman Design Group, an integrated marketing and communications design ... the first and only company in the United States ... exhibition and events industry association. Third party verification of ... or exceeded goals set for nine criteria including greenhouse ...
... Greg Asner has been elected to the National Academy ... and 21 foreign associates from 14 countries elected "in ... research." The total number of active members now stands ... the Department of Global Ecology,s first staff scientist. Since ...
... inventory plots in the Northeast and Midwestern United States contain ... Service study found. The study across two dozen states from ... on the landscape where invasive plants might take root. ... annual forest inventory had at least one introduced species, but ...
Cached Biology News:Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2Carnegie's Greg Asner elected to National Academy of Sciences 2In the Northeast, forests with entirely native flora are not the norm 2